Verquvo FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 25, 2021.
Verquvo (vericiguat) is a soluble guanylate cyclase (sGC) stimulator indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.
- Verquvo is the first soluble guanylate cyclase stimulator approved to treat heart failure.
- Verquvo tablets are taken orally once daily with food.
- The Verquvo product label carries a boxed warning that indicates that Verquvo may cause fetal harm, and should not be administered to pregnant females. Common adverse reactions include hypotension and anemia.
Development timeline for Verquvo
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.